0001104659-24-073000.txt : 20240618
0001104659-24-073000.hdr.sgml : 20240618
20240618212511
ACCESSION NUMBER: 0001104659-24-073000
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240614
FILED AS OF DATE: 20240618
DATE AS OF CHANGE: 20240618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Neill Vincent
CENTRAL INDEX KEY: 0001672718
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38410
FILM NUMBER: 241053836
MAIL ADDRESS:
STREET 1: 2150 WOODWARD ST., SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78744
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001720893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 821386754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-643-8060
MAIL ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
tm2417544-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-06-14
0
0001720893
BioXcel Therapeutics, Inc.
BTAI
0001672718
O'Neill Vincent
C/O BIOXCEL THERAPEUTICS, INC.
555 LONG WHARF DRIVE, 12TH FLOOR
NEW HAVEN
CT
06511
0
1
0
0
See Remarks
1
Common Stock
2024-06-14
4
M
0
521
A
3679
D
Common Stock
2024-06-17
4
S
0
155
1.285
D
3524
D
Restricted Stock Units
2024-06-14
4
M
0
521
0.00
D
Common Stock
521
3648
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Executive Vice President, Chief of Product Development and Medical Officer
/s/ Richard Steinhart, as Attorney in Fact for Vincent O'Neill
2024-06-18